Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients

This study retrospectively reviewed estrogen monotherapy for testosterone suppression in gender diverse individuals assigned male at birth, specifically focusing on transfeminine patients. Out of 10 patients, 7 transfeminine individuals achieved testosterone suppression with serum estradiol levels over 100 pg/mL, using either injectable or transdermal estrogen formulations. Injectable estradiol valerate (4-6 mg weekly) and transdermal patches (0.2 mg twice weekly to 0.3 mg three times weekly) were effective. The study suggests estrogen monotherapy could be a viable alternative to anti-androgens, though the small sample size is a limitation. Further research is needed to confirm these findings and potentially simplify treatment protocols.